CLSD - クリアサイド・バイオメディカル (Clearside Biomedical Inc.)

CLSDのニュース

   The Daily Biotech Pulse: EyePoint In-Licenses Eye Disorder Drug, BioMarin CFO Quits, Rockwell Medical To Offer Shares  2020/02/04 12:51:48 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Feb. 3.) Acceleron Pharma Inc (NASDAQ: XLRN ) Aptose Biosciences Inc (NASDAQ: APTO ) Catalent Inc (NYSE: CTLT ) ( announced a deal to buy cell and gene therapy CDMO MasTherCell and forecast-beating second quarter results) ChemoCentryx Inc (NASDAQ: CCXI ) Clearside Biomedical Inc (NASDAQ: CLSD ) Fate Therapeutics Inc (NASDAQ: FATE ) ITAMAR MED LTD/S ADR (NASDAQ: ITMR ) Molecular Templates Inc (NASDAQ: MTEM ) Orgenesis Inc (NASDAQ: ORGS ) (announced sale of subsidiary MasTherCell to Catalent) Profound Medical Corp (NASDAQ: PROF ) Reata Pharmaceuticals Inc (NASDAQ: RETA ) Repligen Corporation (NASDAQ: RGEN ) Theravance Biopharma Inc (NASDAQ: TBPH ) Down In The Dumps (Biotech stocks that hit 52-week lows Feb. 3.) Alkermes Plc (NASDAQ: ALKS ) Allogene Therapeutics Inc (NASDAQ: ALLO ) Avanos Medical Inc (NYSE: AVNS ) BioLife Solutions Inc (NASDAQ: BLFS ) Blueprint Medicines Corp (NASDAQ: BPMC ) CASI Pharmaceuticals Inc (NASDAQ: CASI ) (moved along with China pharmaceutical stocks due to coronavirus) Endologix, Inc. (NASDAQ: ELGX ) Galectin Therapeutics Inc. (NASDAQ: GALT ) I-Mab (NASDAQ: IMAB ) (went public in mid-January) Intec Pharma Ltd (NASDAQ: NTEC ) TapImmune Inc. (NASDAQ: MRKR ) Omeros Corporation (NASDAQ: OMER ) REDHILL BIOPHAR/S ADR (NASDAQ: RDHL ) Salarius Pharmaceuticals Inc (NASDAQ: SLRX ) X4 …
   Bausch Health and Clearside Biomedical Announce Publication of PIVOTAL Phase 3 Data ON XIPERETM (triamcinolone acetonide suprachoroidal injectable suspension) in Ophthalmology  2020/01/28 12:00:00 PR Newswire
LAVAL, Quebec and ALPHARETTA, Ga., Jan. 28, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") and Bausch + Lomb, its leading global eye health business, and Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company dedicated to developing and…
   The Daily Biotech Pulse: Qiagen Opts To Stay Solo Following Strategic Review, Spectrum Slumps On Negative Data, Microbot Medical To Offer Shares  2019/12/26 12:55:50 Benzinga
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Dec. 24.) Aimmune Therapeutics Inc (NASDAQ: AIMT ) Applied Genetic Technologies Corp (NASDAQ: AGTC ) Cassava Sciences Inc (NASDAQ: SAVA ) ChemoCentryx Inc (NASDAQ: CCXI ) Clearside Biomedical Inc (NASDAQ: CLSD ) DURECT Corporation (NASDAQ: DRRX ) Eiger Biopharmaceuticals Inc (NASDAQ: EIGR ) Esperion Therapeutics Inc (NASDAQ: ESPR ) Exagen Inc (NASDAQ: XGN ) Forty Seven Inc (NASDAQ: FTSV ) Fulcrum Therapeutics Inc (NASDAQ: FULC ) Global Blood Therapeutics Inc (NASDAQ: GBT ) Harpoon Therapeutics Inc (NASDAQ: HARP ) Horizon Therapeutics PLC (NASDAQ: HZNP ) HEALTH SCIENCES/SH (NASDAQ: IMVT ) Intuitive Surgical, Inc. (NASDAQ: ISRG ) Jazz Pharmaceuticals PLC (NASDAQ: JAZZ ) Karyopharm Therapeutics Inc (NASDAQ: KPTI ) Kodiak Sciences Inc (NASDAQ: KOD ) (JPMorgan initiated coverage with an Outperform rating) Microbot Medical Inc (NASDAQ: MBOT ) Mirati Therapeutics Inc (NASDAQ: MRTX ) Momenta Pharmaceuticals, Inc.
   The Daily Biotech Pulse: Axovant Surges On Gene Therapy Study Results, FDA Approves Merck's Ebola Vaccine, Abeona Announces Offering  2019/12/20 13:12:05 Benzinga
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Dec. 19.) Acceleron Pharma Inc (NASDAQ: XLRN ) Ardelyx Inc (NASDAQ: ARDX ) AstraZeneca plc (NYSE: AZN ) Axsome Therapeutics Inc (NASDAQ: AXSM ) (priced its 2-million-share common stock offering at $87 per share) Clearside Biomedical Inc (NASDAQ: CLSD ) Cortexyme Inc (NASDAQ: CRTX ) Cue Biopharma Inc (NASDAQ: CUE ) Exagen Inc (NASDAQ: XGN ) Globus Medical Inc (NYSE: GMED ) Horizon Therapeutics PLC (NASDAQ: HZNP ) HEALTH SCIENCES/SH (NASDAQ: IMVT ) (The acquisition vehicle announced merger with Immuvant, a clinical-stage biopharma company focusing on autoimmune disorders) IVERIC bio Inc (NASDAQ: ISEE ) Johnson & Johnson (NYSE: JNJ ) (Barclays upgraded shares to Overweight) The Medicines Company (NASDAQ: MDCO ) Merck & Co., Inc. (NYSE: MRK ) Mirum Pharmaceuticals Inc (NASDAQ: MIRM ) Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA ) Monopar Therapeutics Inc. (NASDAQ: MNPR ) (Went public Thursday) Myokardia Inc (NASDAQ: MYOK ) NeoGenomics, Inc. (NASDAQ: NEO ) Novan Inc (NASDAQ: NOVN ) Oramed Pharmaceuticals, Inc. (NASDAQ: ORMP ) Principia Biopharma Inc (NASDAQ: PRNB ) Quest Diagnostics Inc (NYSE: DGX ) Recro Pharma Inc (NASDAQ: REPH ) Sanofi SA (NASDAQ: SNY ) SpringWorks Therapeutics Inc (NASDAQ: SWTX ) Down In The Dumps (Biotech stocks that hit 52-week lows Dec. 19.) Aethlon Medical, Inc. (NASDAQ: AEMD ) Anixa Biosciences Inc (NASDAQ: ANIX ) Aridis Pharmaceuticals Inc (NASDAQ: ARDS ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Correvio Pharma Corp (NASDAQ: …
   Clearside Biomedical Shares Rebound On Microinjector Licensing Deal With Regenxbio  2019/09/04 14:20:28 Benzinga
Clearside Biomedical Inc (NASDAQ: CLSD ) shares — which came under intense selling pressure in late August after the company hinted at a possible FDA rejection of the NDA for its macular edema drug — got a reprieve Wednesday. What Happened Clearside announced an option and license agreement with Regenxbio Inc (NASDAQ: RGNX ), granting the latter worldwide rights to its proprietary in-office SCS Microinjector for the delivery of RGX-314 to the suprachoroidal space to treat wet age-related macular degeneration, or AMD; diabetic retinopathy, or DR; and other conditions for which anti-vascular endothelial growth factor treatment … Full story available on Benzinga.com
  クリアサイドバイオメディカルシェアは、Regenxbioとのマイクロインジェクターライセンス契約で反発 Clearside Biomedical Shares Rebound On Microinjector Licensing Deal With Regenxbio  2019/09/04 14:20:28 Benzinga
「Clearside Biomedical Inc(NASDAQ:CLSD)株-黄斑浮腫薬に対するNDAのFDA拒否の可能性を示唆した後、8月下旬に激しい販売圧力を受けた水曜日に猶予が与えられました。 Regenxbio Inc(NASDAQ:RGNX)とのライセンス契約により、加湿性加齢黄斑変性症またはAMDの治療のために脈絡膜上腔にRGX-314を送達する独自の社内SCSマイクロインジェクターの世界的な権利を後者に付与し、またはDR;および抗血管内皮増殖因子治療のその他の条件…Benzinga.comで利用可能な全容
Clearside Biomedical Inc (NASDAQ: CLSD ) shares — which came under intense selling pressure in late August after the company hinted at a possible FDA rejection of the NDA for its macular edema drug — got a reprieve Wednesday. What Happened Clearside announced an option and license agreement with Regenxbio Inc (NASDAQ: RGNX ), granting the latter worldwide rights to its proprietary in-office SCS Microinjector for the delivery of RGX-314 to the suprachoroidal space to treat wet age-related macular degeneration, or AMD; diabetic retinopathy, or DR; and other conditions for which anti-vascular endothelial growth factor treatment … Full story available on Benzinga.com
   The Daily Biotech Pulse: EC Nod For Bristol-Myers Squibb, Kyowa Kirin's Parkinson's Add-On Therapy Approved  2019/08/28 11:31:33 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 27) Castle Biosciences Inc (NASDAQ: CSTL ) The Medicines Company (NASDAQ: MDCO ) Down In The Dumps (Biotech stocks hitting 52-week lows on Aug. 27) Abeona Therapeutics Inc (NASDAQ: ABEO ) Advaxis, Inc. (NASDAQ: ADXS ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Alder Biopharmaceuticals Inc (NASDAQ: ALDR ) Aldeyra Therapeutics Inc (NASDAQ: ALDX ) Alimera Sciences Inc (NASDAQ: ALIM ) AnaptysBio Inc (NASDAQ: ANAB ) ASLAN PHARMACEU/ADR (NASDAQ: ASLN ) Assembly Biosciences Inc (NASDAQ: ASMB ) Cancer Genetics Inc (NASDAQ: CGIX ) Catalyst Biosciences Inc (NASDAQ: CBIO ) Clearside Biomedical Inc (NASDAQ: CLSD ) Crinetics Pharmaceuticals Inc (NASDAQ: CRNX ) DelMar Pharmaceuticals Inc (NASDAQ: DMPI )(announced that its current cash position will be sufficient to complete enrollment in all three patient groups of its two ongoing Phase 2 trials for its lead compound VAL-083, which is likely to occur by the fourth quarter of 2020) ICU Medical, Incorporated (NASDAQ: ICUI ) Kala Pharmaceuticals Inc (NASDAQ: KALA ) Mallinckrodt PLC (NYSE: MNK )(reacted to an unfavorable ruling on a patent infringement lawsuit regarding its inhaled nitric oxide product) Neuralstem, Inc. (NASDAQ: CUR ) Novus Therapeutics Inc (NASDAQ: NVUS ) Obalon Therapeutics Inc (NASDAQ: OBLN ) Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) Regenxbio Inc (NASDAQ: RGNX ) Revance Therapeutics Inc (NASDAQ: RVNC )(announced an amended agreement with Mylan NV (NASDAQ: MYL ), …
   The Daily Biotech Pulse: Nuvectra Explores Strategic Options, J&J To Contend Opioid Ruling, Sesen Bio Gets New CFO  2019/08/27 11:29:00 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 26) DURECT Corporation (NASDAQ: DRRX ) Stoke Therapeutics Inc (NASDAQ: STOK ) Down In The Dumps (Biotech stocks hitting 52-week lows on Aug. 26) Advaxis, Inc. (NASDAQ: ADXS ) Arbutus Biopharma Corp (NASDAQ: ABUS ) ASLAN PHARMACEU/ADR (NASDAQ: ASLN ) Avanos Medical Inc (NYSE: AVNS ) Cancer Genetics Inc (NASDAQ: CGIX ) Clearside Biomedical Inc (NASDAQ: CLSD ) Elanco Animal Health Inc (NYSE: ELAN )(Bank of America downgraded the shares to Neutral) Neurometrix Inc (NASDAQ: NURO ) Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) Stealth BioTherapeutics Corp (NASDAQ: MITO ) Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH ) Tocagen Inc (NASDAQ: TOCA ) Unity Biotechnology Inc (NASDAQ: UBX ) Zafgen Inc (NASDAQ: ZFGN ) Stocks In Focus Nuvectra To Explore Strategic Options Nuvectra Corp (NASDAQ: NVTR ) announced its decision to explore strategic alternatives to …
   Clearside Stock Plummets After Company Hints At Complete Response Letter For Macular Edema Drug  2019/08/22 15:20:09 Benzinga
Clearside Biomedical Inc (NASDAQ: CLSD ) shares entered penny stock territory Thursday after the company issued an update on what transpired at a meeting with the FDA regarding the new drug application for Xipere. What Happened In a meeting this week, the FDA's Office of Pharmaceutical Quality sought stability data for the triamcinolone acetonide, or TA, suspension produced utilizing an enhanced manufacturing process enacted by the company, Clearside said Thursday. The company submitted an NDA through the 505(b)(2) pathway seeking approval for Xipere, chemically triamcinolone acetonide suprachoroidal injectable suspension. The agency accepted the application Feb. 20 and assigned a PDUFA date of Oct. 19. Xipere is being evaluated for treating patients with macular edema associated … Full story available on Benzinga.com
   Clearside Biomedical, Inc. (CLSD) Reports Q2 Loss, Misses Revenue Estimates  2019/08/08 00:25:10 Zacks Investment Research
Clearside Biomedical, Inc. (CLSD) delivered earnings and revenue surprises of 59.46% and -10.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
   Clearside Biomedical, Inc. (CLSD) CEO George Lasezkay on Q1 2019 Results - Earnings Call Transcript  2019-05-08
Clearside Biomedical, Inc. (CLSD) Q1 2019 Earnings Conference Call May 08, 2019, 08:30 AM ET Company Participants Jenny Kobin - IR George Lasezkay - Interim CEO Thomas Ciulla - Chief Medical Officer Brion Raymond - Chief Commercial Officer Charlie Deignan - CFO Conference …
   Clearside Biomedical beats by $0.02  2019-05-08
Clearside Biomedical (NASDAQ: CLSD ): Q1 GAAP EPS of -$0.45 beats by $0.02. More news on: Clearside Biomedical, Inc., Earnings news and commentary, Healthcare stocks news, , Read more …

calendar